

**Research**

AVI BioPharma announces  
exon skipping trial results

Prosen's Clinical  
Development Plan Update

ImagingDMD National  
Study Recruiting Patients

**News**

8-Year-Old to Climb Mt.  
Kilimanjaro to Cure  
Duchenne Muscular  
Dystrophy

Form a Climb to  
CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne  
Research

Sally and Mack Brown host  
3rd Annual Champions to  
CureDuchenne Fundraiser  
at The University of Texas  
Golf Club

Young Professionals Rally  
Around CureDuchenne

Shop to CureDuchenne

**Recent Successes**

AVI Announces Top Line  
Results for Exon Skipping  
Trial

**Family of the Month**

The Rothe Family

**Scientist of the Month**

Barry Byrne, M.D., Ph.D.

**Upcoming Events**

Champions to  
CureDuchenne Austin  
Gala, April 27, 2012,  
Austin, TX

Dealing for Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June 2,

## AVI BioPharma announces exon skipping trial results

**30mg dose raises dystrophin 22.5 percent in 24 weeks**

**\* No improvement seen in clinical outcomes**

*By Deena Beasley*

**April 2 (Reuters)** A small trial of U.S.-based AVI BioPharma Inc's experimental muscular dystrophy drug met its goal of increasing levels of a key protein, but did not demonstrate that the drug had an impact on walking ability or other clinical endpoints.

The mid-stage trial, or Phase IIb, which involved 12 boys with Duchenne muscular dystrophy, found that the four patients treated for 24 weeks with a 30 mg dose of the drug, eteplirsen, had a 22.5 percent average increase in levels of dystrophin, a protein essential to building muscle, compared to no increase for four patients treated with a placebo.

Duchenne muscular dystrophy — a muscle degeneration disease affecting young children, almost exclusively boys — leads to paralysis and death in young adulthood. At least 250,000 people worldwide are believed to be afflicted with the disease.

Eteplirsen is designed to silence a specific strand of RNA so that the body can produce the dystrophin that people with Duchenne muscular dystrophy are unable to produce.

The trial found that the four patients treated for 12 weeks with a 50 mg dose of the drug did not show a significant increase in dystrophin, suggesting that a longer duration of dosing is needed. It also found no significant improvements in clinical outcomes, including a six-minute walk test, in the treated groups compared to placebo.

"We anticipate that these levels of dystrophin could lead to significant clinical benefit if maintained over a longer course of treatment," Dr. Jerry Mendell, director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital in Columbus, Ohio and the study's lead investigator, said in a statement.

There were no treatment-related adverse events, no serious side effects, and no evidence of kidney toxicity.

AVI BioPharma Chief Executive Officer Chris Garabedian said the company plans to discuss with U.S. regulators how best to conduct a longer pivotal trial of the drug.

"The hope is that if we can delay or halt the progression of the disease we would be able to avoid these kids ending up in a wheelchair," he said. "It would avoid the need for ventilators, maybe even prevent death."

Eteplirsen is designed to skip a specific "exon," or protein-coding sequence of the dystrophin gene that is mutated in about 15 percent of people with Duchenne muscular dystrophy.

AVI BioPharma is also developing drugs targeting other exon mutations responsible for muscular dystrophy.

Garabedian said he would prefer raising funding for a pivotal trial from capital markets, rather than a partnership.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

"In the rare disease area, it doesn't take a large commercial infrastructure to do this," he said.

[Click Here to Read the Press Release](#)

**Research**

AVI BioPharma announces  
exon skipping trial results

Prosen's Clinical  
Development Plan Update

ImagingDMD National  
Study Recruiting Patients

**News**

8-Year-Old to Climb Mt.  
Kilimanjaro to Cure  
Duchenne Muscular  
Dystrophy

Form a Climb to  
CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne  
Research

Sally and Mack Brown host  
3rd Annual Champions to  
CureDuchenne Fundraiser  
at The University of Texas  
Golf Club

Young Professionals Rally  
Around CureDuchenne

Shop to CureDuchenne

**Recent Successes**

AVI Announces Top Line  
Results for Exon Skipping  
Trial

**Family of the Month**

The Rothe Family

**Scientist of the Month**

Barry Byrne, M.D., Ph.D.

**Upcoming Events**

Champions to  
CureDuchenne Austin  
Gala, April 27, 2012,  
Austin, TX

Dealing for Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June 2,

## AVI BioPharma announces exon skipping trial results

**30mg dose raises dystrophin 22.5 percent in 24 weeks**

**\* No improvement seen in clinical outcomes**

*By Deena Beasley*

**April 2 (Reuters)** A small trial of U.S.-based AVI BioPharma Inc's experimental muscular dystrophy drug met its goal of increasing levels of a key protein, but did not demonstrate that the drug had an impact on walking ability or other clinical endpoints.

The mid-stage trial, or Phase IIb, which involved 12 boys with Duchenne muscular dystrophy, found that the four patients treated for 24 weeks with a 30 mg dose of the drug, eteplirsen, had a 22.5 percent average increase in levels of dystrophin, a protein essential to building muscle, compared to no increase for four patients treated with a placebo.

Duchenne muscular dystrophy — a muscle degeneration disease affecting young children, almost exclusively boys — leads to paralysis and death in young adulthood. At least 250,000 people worldwide are believed to be afflicted with the disease.

Eteplirsen is designed to silence a specific strand of RNA so that the body can produce the dystrophin that people with Duchenne muscular dystrophy are unable to produce.

The trial found that the four patients treated for 12 weeks with a 50 mg dose of the drug did not show a significant increase in dystrophin, suggesting that a longer duration of dosing is needed. It also found no significant improvements in clinical outcomes, including a six-minute walk test, in the treated groups compared to placebo.

"We anticipate that these levels of dystrophin could lead to significant clinical benefit if maintained over a longer course of treatment," Dr. Jerry Mendell, director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital in Columbus, Ohio and the study's lead investigator, said in a statement.

There were no treatment-related adverse events, no serious side effects, and no evidence of kidney toxicity.

AVI BioPharma Chief Executive Officer Chris Garabedian said the company plans to discuss with U.S. regulators how best to conduct a longer pivotal trial of the drug.

"The hope is that if we can delay or halt the progression of the disease we would be able to avoid these kids ending up in a wheelchair," he said. "It would avoid the need for ventilators, maybe even prevent death."

Eteplirsen is designed to skip a specific "exon," or protein-coding sequence of the dystrophin gene that is mutated in about 15 percent of people with Duchenne muscular dystrophy.

AVI BioPharma is also developing drugs targeting other exon mutations responsible for muscular dystrophy.

Garabedian said he would prefer raising funding for a pivotal trial from capital markets, rather than a partnership.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

"In the rare disease area, it doesn't take a large commercial infrastructure to do this," he said.

[Click Here to Read the Press Release](#)

### Research

AVI BioPharma announces exon skipping trial results

Prosensa's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Prosensa's Clinical Development Plan Update

In parallel to the on-going development of the lead compound PRO051/GSK2402968, which is being developed by GSK with an active involvement of Prosensa, there are five more compounds for Duchenne in Prosensa's pipeline. Below you can find an update about the current state of development of these compounds.

Prosensa is currently conducting a clinical study to investigate the effect of PRO044 in boys with Duchenne muscular dystrophy, who have a dystrophin gene mutation amenable to an exon 44 skip. This study is a phase I/IIa study that will assess the safety, tolerability, efficacy and pharmacokinetics of PRO044. The inclusion/exclusion criteria, as well as the endpoints and investigator locations are available on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (search terms 'Duchenne and Prosensa' or 'PRO044').

Prosensa has four additional compounds in development that target exons 45, 53, 52 and 55 (PRO045, PRO053, PRO052 and PRO055). These programs currently are in the pre-clinical development phase. It is anticipated that the company will be able to progress PRO045 and PRO053 into the clinic in the second half of 2012. Discussions are on-going with the regulatory authorities to ensure optimum development. Each trial will be posted at the website [www.clinicaltrials.gov](http://www.clinicaltrials.gov) as soon as the study design is finalized and all the required approvals of authorities and ethics committees are granted.

It is always difficult to predict timelines for drug development. Therefore, please keep in mind that expected start and end dates are based on predictions and could be delayed if unforeseen events occur.

Prosensa is very committed to developing safe and effective treatments and we will do our utmost to succeed herein. Our goal is to develop compounds for as many patients as feasible who may benefit from the exon skipping platform.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

**Research**

AVI BioPharma announces  
exon skipping trial results

Prosenza's Clinical  
Development Plan Update

ImagingDMD National  
Study Recruiting Patients

**News**

8-Year-Old to Climb Mt.  
Kilimanjaro to Cure  
Duchenne Muscular  
Dystrophy

Form a Climb to  
CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne  
Research

Sally and Mack Brown host  
3rd Annual Champions to  
CureDuchenne Fundraiser  
at The University of Texas  
Golf Club

Young Professionals Rally  
Around CureDuchenne

Shop to CureDuchenne

**Recent Successes**

AVI Announces Top Line  
Results for Exon Skipping  
Trial

**Family of the Month**

The Rothe Family

**Scientist of the Month**

Barry Byrne, M.D., Ph.D.

**Upcoming Events**

Champions to  
CureDuchenne Austin  
Gala, April 27, 2012,  
Austin, TX

Dealing for Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June 2,

**ImagingDMD National Study Recruiting Patients**

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) were recently awarded a 5-year multi-million dollar research grant to investigate the potential of magnetic resonance imaging (MRI) to noninvasively monitor disease progression in Duchenne muscular dystrophy.

Known as "ImagingDMD," the study is a joint effort between researchers at the University of Florida, The Children's Hospital of Philadelphia and Shriners Hospital for Children-Portland, Oregon Health and Science University. The study is led by Dr. Krista Vandeborne of University of Florida, the study's director along with Dr. Lee Sweeney of University of Pennsylvania, the study's co-director.

Researchers will study the leg muscles of 100 boys with Duchenne muscular dystrophy, ages 5 to 14, that are still able to walk, using MRI and various functional tests. The study will investigate whether MRI can be used as an outcome measure to help researchers determine the effect of different treatment interventions in clinical trials, replacing the use of muscle biopsies.

Additionally, the multi-site study will examine the effect of starting corticosteroids on muscle physiology and muscle function in a small group of boys. A small skin sample will be taken from each boy and stored in tissue data banks for future testing of new drugs.

In order to participate in this study children must have the gene abnormality (mutation) associated with DMD. All boys with DMD who are between 5 and 14 years of age that are able to walk 100 meters (the length of a football field) and still climb four stairs are eligible for this project; with the exception of those with implants (materials or devices that are not MRI compatible).

For more information visit [www.ImaginingDMD.org](http://www.ImaginingDMD.org).

[Click here to read the ImagingDMD Brochure](#)

[Click here to read the ImagingDMD Flyer](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.



### Research

AVI BioPharma announces exon skipping trial results

Prosensa's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## 8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy



Tyler Armstrong

Eight-year-old Tyler Armstrong, of Yorba Linda, Calif., has set his sights on becoming one of the youngest ever to summit one of the highest mountains in the world, Mt. Kilimanjaro. He already set a record as the youngest person to climb Mt. Whitney in a single day the highest peak in the contiguous United States. Showing remarkable compassion, Tyler decided he would climb Mt. Kilimanjaro not for himself, but for the 300,000 boys worldwide who suffer from Duchenne muscular dystrophy and for his friend 12-year-old Suhail Zaveri of Anaheim.

"I am doing this climb to help Suhail and other boys my age that have Duchenne because most of them have a hard time even walking," said Tyler.

CureDuchenne is coordinating Tyler's climb as part of the fourth annual [Climb to CureDuchenne Pick Your Peak event](#). If everything goes as planned, Tyler, due to special permission granted by the Tanzanian government, will be the second youngest to reach the 19,341 foot summit of Mt. Kilimanjaro and the youngest

person to lead a fundraiser of this caliber for a nonprofit.

Achieving this impressive athletic goal requires a dedicated family, impressive athletic ability, a strict training regiment including four-mile runs coupled with an intensive [training climb schedule](#). Achieving this compassionate goal requires a heartfelt want to help others who cannot do what he can. "Boys with Duchenne, Tyler, and CureDuchenne all seem to have one thing in common determination," said Debra Miller, founder and CEO of CureDuchenne. "We are thrilled Tyler decided to climb Mt. Kilimanjaro to help find a cure for Duchenne muscular dystrophy on behalf of the Duchenne boys who can't."

Others can participate in [Climb to CureDuchenne Pick Your Peak](#) by choosing any mountain, hill or tall building to climb on June 23 or June 30, 2012. Anyone, regardless of athletic ability, is encouraged to participate individually or to form a team and secure sponsors/contributors to raise funds to find a cure for Duchenne. Click here to [donate](#) to the climb. To learn more about Tyler visit [TopWithTyler.com](#).

Travel Dirty is the official travel sponsor for the Mt. Kilimanjaro climb. The international travel agency caters to those who want their vacations to include both stunning locations and athletic adventures.

[Click to Read Our Press Release](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

### Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Form a Climb to CureDuchenne Team

Join us for the fourth annual [Climb to CureDuchenne Pick Your Peak 2012](#). You can help find a cure for Duchenne muscular dystrophy. It's simple, it's local and it's fun. Choose a mountain, hill or tall building to climb in order to increase awareness about Duchenne and help raise funds to support our promising research projects and find treatments to save our sons' lives. With your help, we can make it to the peak.



Last year team Hawken's Heros climbed Grand Teton in Wyoming as part of the Climb to CureDuchenne Pick Your Peak.

We invite you to form a team, set up a fundraising page, secure personal sponsors/contributors and Climb to CureDuchenne on June 23 or June 30 (other dates may be substituted). There are no geographical or athletic ability limitations. You pick where you want to walk, hike or climb. You can also join a team or donate without climbing.

This year we have an elite team climbing Mt. Kilimanjaro June 25-July 2. This team includes 8-year-old Tyler Armstrong of Yorba Linda, Calif. After obtaining special permission by the Tanzanian government, Tyler will be the second youngest person ever to climb Mount Kilimanjaro. His ascent to the 19,341 ft. summit will help raise funds and awareness for CureDuchenne. Tyler became interested in helping boys who aren't able to take on the challenges of mountain climbing when he met a Duchenne boy close to his age who is wheelchair-bound. Even at the age of 8, Tyler realized he could use his athletic abilities to help others. Tyler will represent the more than 300,000 boys worldwide when he faces this epic, eight-day challenge and adventure. To donate to Team Tyler [click here](#).

We hope you'll set your own personal climbing challenge, big or small, to help us conquer Duchenne. Do it yourself or put together a team and encourage your friends, family and colleagues to sponsor your climb. You can register and set up your fundraising page by [clicking here](#). It costs \$25 to participate, which includes a CureDuchenne t-shirt.

To get motivated, watch our Pick Your Peak [video](#).

For more information and resources to promote Climb to CureDuchenne in your community, call Karen Harley at 949-872-2552.

[Click Here to Read the Pick Your Peak Overview](#)

[Click Here to Read the Team Captain Guidelines](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

**Research**

AVI BioPharma  
announces exon  
skipping trial results

Prosensa's Clinical  
Development Plan  
Update

ImagingDMD  
National Study  
Recruiting Patients

**News**

8-Year-Old to Climb  
Mt. Kilimanjaro to  
Cure Duchenne  
Muscular Dystrophy

Form a Climb to  
CureDuchenne  
Team

I Am a Duchenne  
Dad

Fundraising for  
Duchenne Research

Sally and Mack  
Brown host 3rd  
Annual Champions  
to CureDuchenne  
Fundraiser at The  
University of Texas  
Golf Club

Young Professionals  
Rally Around  
CureDuchenne

Shop to  
CureDuchenne

**Recent  
Successes**

AVI Announces Top  
Line Results for  
Exon Skipping Trial

**Family of the  
Month**

The Rothe Family

**Scientist of the  
Month**

## I Am a Duchenne Dad



Paul Miller, Cure Duchenne co-founder, has created an "I Am a Duchenne Dad" online community, a new Facebook group to connect with other dads and share information about supporting their sons with Duchenne muscular dystrophy.

"Many fathers of Duchenne sons are working full time to support their families, and then working full time to support their son's health and physical limitations," said Miller. "I know there are many dads like me who would like to connect and talk about what works for us and learn what works for others in balancing the needs of our sons who are afflicted with Duchenne with the needs of our entire family."

The "I Am a Duchenne Dad" community will discuss positive ways to improve the lives of families such as:

- Sharing creative activities that Duchenne boys can participate in
- Improving your son's health through physical therapy and nutrition
- Increasing the father's strength and endurance to be equipped to deal with the demands of a weakening child
- Keeping up to date on research and finding ways to support research projects
- Finding solutions to cope with the disease
- Sharing spiritual support

If you are interested in sharing your experience as a Duchenne dad and learning from others, send a friend request to: <http://www.facebook.com/#!/pfmiller>

Miller began the Duchenne Dad blog back in 2004 and is now bringing it to the community as a Facebook page. Like all dads, Miller is hopeful that he can help his son achieve a happy and meaningful life and he looks forward to connecting with like-minded dads around the world. To read Miller's most recent blog, go to: <http://www.cureduchenneblog.org/?p=487>

Barry Byrne, M.D.,  
Ph.D.

## Upcoming Events

Champions to  
CureDuchenne  
Austin Gala, April 27,  
2012, Austin, TX

Dealing for  
Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June  
2, 2012, Los Angeles

Climb to  
CureDuchenne, Pick  
Your Peak, June 23  
and June 30,  
Nationwide

Getzlaf Golf  
Shootout,  
September 8-9,  
2012, Dana Point,  
Calif.



*"Together we can CureDuchenne"*

April 2012

### Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Fundraising for Duchenne Research

Call Karen Harley at 949-872-2552 or [karen@cureduchenne.org](mailto:karen@cureduchenne.org) if you would like to raise funds for Duchenne research. CureDuchenne can help you turn your ideas and passions into funding that will help accelerate Duchenne research.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.



### Research

AVI BioPharma announces exon skipping trial results

Prosensa's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Sally and Mack Brown will host the third annual Champions to CureDuchenne presented by RBC Wealth Management on April 27, 2012 at The University of Texas Golf Club (2200 University Club Drive, Austin, TX). Cost is \$150 per person and includes admission, food and beverages. Champions to CureDuchenne is a fundraiser for CureDuchenne, which funds groundbreaking research to save the 300,000 boys worldwide who have Duchenne.



Mack Brown, head coach of the Texas Longhorns at the University of Texas, and eight-year-old Timothy Revell.

In 2011, more than 500 guests joined Sally and Mack Brown including coaching staff, celebrities, and former UT players like Vince Young, Ricky Williams, Colt McCoy and more.

This year, guests dressed in "cowboy chic" will enjoy a relaxed evening that will feature chefs from eight Austin area restaurants including Vince Young Steakhouse, Max's Wine Dive, Steiner Ranch Steakhouse, Zax, Cook Well & Co., The League, Moonshine and University of Texas Golf Club. Several of the restaurants will also be donating a week sales of an item on their menu to CureDuchenne.

Guests will also enjoy live music from the Hot Club of Cowtown, wine from Duchman Family Winery, beer from Thirsty Planet Brewing, and signature Bevo-ritas with Dulce Vida Organic Tequila. Other sponsors include Covert Cadillac, AT&T and Carino's Italian. The evening also includes a silent and live auction and an inspirational program including remarks by Mack Brown.

"This year we will build on the momentum of previous Champions to CureDuchenne events that have raised funds that have gone directly to key research projects," said Tim Revell, Duchenne parent and event organizer. "We have created a signature event in Austin, and we will continue to raise awareness and funds to push the research to ultimately find a cure."

Sponsorship and ticket purchasing information can be found at the Champions to CureDuchenne website at [www.championstocureduchenne.org](http://www.championstocureduchenne.org).

KUVE-Austin Tim Revel interview

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

### Research

AVI BioPharma announces  
exon skipping trial results

Prosen's Clinical  
Development Plan Update

ImagingDMD National  
Study Recruiting Patients

### News

8-Year-Old to Climb Mt.  
Kilimanjaro to Cure  
Duchenne Muscular  
Dystrophy

Form a Climb to  
CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne  
Research

Sally and Mack Brown host  
3rd Annual Champions to  
CureDuchenne Fundraiser  
at The University of Texas  
Golf Club

Young Professionals Rally  
Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line  
Results for Exon Skipping  
Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to  
CureDuchenne Austin  
Gala, April 27, 2012,  
Austin, TX

Dealing for Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June 2,

## Young Professionals Rally Around CureDuchenne

CureDuchenne will host a young professional happy hour on April 18 in Corona Del Mar, Calif. This networking event allows young professionals to engage in a unique texting fundraiser that allows them to give back to the community in a fun easy way. Guests donate a cover charge to CureDuchenne which includes a raffle ticket for a chance to win a \$1,000 Montage Resort Laguna Beach stay and dinner.

While at the happy hour, young professionals will post on Facebook and tweet about the texting campaign, encouraging their friends and followers to text SAVE to 80888 to donate \$10. For more information on the texting campaign, go to [www.texttocure.org](http://www.texttocure.org). Thank you to community leaders Brandon Burton and Alex Goldberg from Northwestern Mutual and Mijanou Pham from Socially Sweet Events for chairing the event.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

## Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

## News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

## Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

## Family of the Month

The Rothe Family

## Scientist of the Month

Barry Byrne, M.D., Ph.D.

## Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Shop to CureDuchenne

There are several ways you can shop and support CureDuchenne at the same time.

### Nationally

Spring is here. It is the perfect time to shop for fruit baskets, bath and body products, candles and other items for Mother's Day. CureDuchenne has an online [fundraising gift store](#) provided by Phil's Shop. The online store offers cookies and cakes, fruit baskets, BBQ items and an array of picnic baskets. The store recently added toys from Melissa and Doug as part of its offering. A significant portion of the purchase price is donated directly to CureDuchenne.

"CureDuchenne is always looking for creative ways to raise funds to find a cure for Duchenne," said Debra Miller, founder and CEO of CureDuchenne. "Our fundraising store offers consumers an opportunity to feel good about the gifts they purchase because they know that in addition to buying a gift for a loved one or friend they are also giving hope to young boys who have Duchenne."

Additional gift options are added to the site monthly. The gifts are perfect for birthdays, Mother's Day, Father's Day, housewarming and other occasions. Gifts are sent along with a gift message directly from the store to recipients and every purchase generates a donation that goes directly to CureDuchenne.

We encourage you to check it out and shop to CureDuchenne.

[Click here to visit CureDuchenne at Phil's Shops](#)

### Orange County, Calif.

Imagine a world where you buy a new SUV and the dealer donates \$400 back to CureDuchenne. Or you take your family out to dinner, and the restaurant donates \$15 to CureDuchenne. Thanks to our partnership with Communities for Cause (CfC), we are making this a reality. This program, "Shop for CureDuchenne," uses a simple smart phone app that lets you earn donations from a variety of local businesses when you make a purchase.

Getting started is quick and easy. iPhone users simply [click here](#) to download the free phone app. Android users [click here](#). Launch the app, register, and select CureDuchenne as your charitable organization. Now you are ready to shop and dine. Visit our merchants and let them know you are part of the Communities for Cause program when you shop or dine.

Download the app now and you can win a summer stay in Mammoth Lakes. The person who uses Communities for Cause to benefit CureDuchenne the most times in the first two months of the program (April 6 through June 6) will win a week's stay (valid through October 31, 2012) at a beautiful Chamonix condo in Mammoth Lakes. This two-bedroom + loft unit (sleeps eight) and is located near Canyon Lodge. Enjoy hiking, mountain biking, the pool, spa deck and beautiful grounds. Dates to be worked out with owner.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

Connecting the causes you care about...  
with the places you shop



**COMMUNITIES  
FOR CAUSE**

### Online

DopeHut is a brand new online streetwear store based in the San Francisco area offering over 30 brands of cool, hip clothing. Its mission is to promote creativity, be idealistic and do good while benefitting customers, clients, employees, partners, investors, the environment and society. DopeHut is offering CureDuchenne an exclusive coupon code "curecd". The coupon code is for 15 percent off entire orders. CureDuchenne will receive 8 percent of the entire sale each time someone uses this coupon. [www.dopehut.com](http://www.dopehut.com)



### Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## AVI Announces Top Line Results for Exon Skipping Trial

Another one of CureDuchenne's funded research projects achieves a significant milestone.

AVI Biopharma announced the top line results from their phase 2 trial for Eteplirsen, a drug which induces exon skipping in patients amenable to a skip of exon 51.

Chris Garabedian, CEO of AVI shared the top line results showing after 24 weeks, four patients on the 30 mg. dose had an average increase of dystrophin of 22.5 percent. The patients who received the 50 mg. dose for 12 weeks did not show an increase in dystrophin, suggesting duration of treatment is important.

"I always caution families, we still don't know if exon skipping will actually become a real treatment for our sons with Duchenne, or to what extent it will help them," said Debra Miller, president and founder of CureDuchenne. On a conference call on April 2 announcing these results, AVI's Chief Medical Officer Ed Kaye referred to "reasonable" dystrophin needed to function as 20 percent, so this study does indeed give us proof of concept and hope that we might have a treatment sometime in the future.

Dr. Eric Hoffman, at Children's National Medical Center in Washington D.C., spearheaded collaboration with CNMC along with the Foundation to Eradicate Duchenne and CureDuchenne several years ago. This collaboration gave critical funding to AVI at a very crucial time which allowed them to move forward with the preclinical work necessary to progress into this phase 2 human clinical trials. Dr. Jerry Mendell and Dr. Kevin Flanigan, at Nationwide Children's Hospital in Columbus, Ohio have played a pivotal role in conducting this trial over the last several months.

"We are very grateful to these investigators and organizations for their vision and dedication," said Miller.

What Comes Next?

There's a song named "Two Out Of Three Ain't Bad." We now have reasonable data that suggests the drug is safe, as there were no adverse event. And, we know the drug can produce dystrophin, and at a reasonable amount. Now, the big question is whether this quality/quantity of dystrophin will result in meaningful outcome measures and really help Duchenne patients live longer and healthier lives.

All patients, including the placebo groups that were on the phase 2, are now on the open label extension study at either the 30 mg. or 50 mg. dose. They will stay on this dose until they complete a total of 48 weeks dosing, at which time a biopsy will be taken and clinical outcome measures tested. In the meantime, AVI will be actively involved with the FDA, compiling a brief and planning the pivotal phase 3 study. Simultaneously, more animal studies will be conducted. Since the FDA most likely will not accept the presence of dystrophin alone as justification to move forward with Eteplirsen, this extension phase and the data they gather will be very important. The first patient to be dosed began in August of 2011, which would make this data available later this year.

As we await the clinical outcomes of the extension trial, AVI will be busy looking to the future,

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

and CureDuchenne is equipped and ready to support their subsequent research on additional exons and next generation exon skipping compounds. CureDuchenne will always fund research projects that show more immediate potential to help our Duchenne sons, such as already approved FDA drugs to slow the progression. But CureDuchenne will never take its eye off the prize...to correct the actual defect that causes this terrible disease. CureDuchenne is committed to fund research, like exon skipping, that will replace the missing dystrophin protein, at the same time funding more immediate research that could get FDA approved or off-target drugs to keep our sons going in order to take advantage of these higher impact drugs.

CureDuchenne was also the first US organization to support Prosensa, another exon skipping biotech company. Prosensa was able to leverage our funds and received a commitment of up to \$650 million to develop their drugs and is in the process of recruiting patients for its phase 3 pivotal trial.

Two out of three may not be bad, but it's not enough. So please rejoice in the possibility of an effective treatment, while at the same time show restraint with our expectations, since so many drugs do fail, even at late stage trials. One thing is for sure...we need all of you to support these research efforts.



### Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Family of the Month - The Rothe Family



Jessica and Ted Rothe with former Dallas Cowboy Rocket Ismail and nine-year-old Nathan Rothe and his friend Collin promoting the Texas Escalade challenge which resulted in a Public Service Announcement campaign.

Three thousand miles from his physical therapist and doctors, Nathan Rothe, a 9-year-old boy living with Duchenne Muscular Dystrophy, experienced the role of an Alaskan musher and the immense power and speed behind a sled dog team in the Iditarod. Nathan lived a week-long Alaskan experience, including the highly coveted role of IditaRider. As an IditaRider, Nathan travelled the first leg of the race, approximately 11 miles through Anchorage with a musher through Make A Wish Foundation.

Ted and Jessica Rothe found out that their son Nathan had Duchenne at the age of 5 when they noticed he had trouble hopping, jumping

and running. "It was devastating to find out there is no cure or treatment available to help our son," said Jessica Rothe. The Rothe family, from Highland Village, Texas, have been actively fundraising to help find a cure for Duchenne.

The Rothe family recently participated in a Public Service Announcement and an interview on "Good Morning Texas" with Rocket Ismail, former Dallas Cowboy, on behalf of CureDuchenne to help increase awareness about Duchenne. They promoted the Text 2 CureDuchenne campaign to encourage people to text SAVE to 80888 to donate \$10 through the media and through their local school district.

The Rothe's also ran a 5K in the Austin Marathon to support CureDuchenne.

"I have a hard time keeping up with my friends and running," said Nathan. "I want to find a cure so I can play sports with all my friends. I would like to play baseball for the Texas Rangers."

[Click here to see the PSA.](#)

Watch the Good Morning Texas interview:

Good Morning Texas CureDuchenne Interview

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.



### Research

AVI BioPharma announces exon skipping trial results

Prosensa's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Scientist of the Month


Barry Byrne, M.D., Ph.D. is a pediatric cardiologist. He is a professor and associate chair of pediatrics and Molecular Genetics & Microbiology and Director of the University of Florida Powell Gene Therapy Center.

Byrne's research is aimed at understanding several types of inherited muscle disease, which lead to heart and skeletal muscle dysfunction. His primary involvement lies with disorders such as Pompe, congenital muscular dystrophy and Duchenne muscular dystrophy, focusing on the associated cardiomyopathy in these conditions. Byrne is actively working on a gene therapy approach in muscular dystrophy especially where cardiopulmonary dysfunction is not effectively managed by the current approach.

"We are mindful of developing treatments that will improve heart and lung as well as skeletal muscle functions," said Byrne. "Families should speak to their cardiologists about early treatment of cardiomyopathy which could ultimately impact their child's long term outcome."

Byrne is currently training for this year's Climb to CureDuchenne Pick Your Peak. He is joining the elite team climbing Mt. Kilimanjaro on June 25-July 2, along with 8-year-old Tyler Armstrong (see separate article). Since there are no mountains in Florida, Byrne is biking (60 miles per week), swimming and climbing the Florida football stadium to prepare for the climb. Byrne has participated in all of the previous Climb to CureDuchenne Pick Your Peak events including climbing Mt. Rainer and Grand Teton.

"I'm looking forward to this year's adventure on Mt. Kilimanjaro," said Byrne. "I hope Tyler is strong enough to carry or assist all the adults to the summit," he cheerfully added.



Barry Byrne, M.D., Ph.D., professor and associate chair of pediatrics and Molecular Genetics & Microbiology and Director of the University of Florida Powell Gene Therapy Center.

## Interview with Dr. Barry Byrne, M.D., Ph.D.

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.





*"Together we can CureDuchenne"*

April 2012

### Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Sally and Mack Brown, head coach for the University of Austin Texas Longhorns, will host the third annual Champions to CureDuchenne presented by RBC Wealth Management on April 27, 2012 at The University of Texas Golf Club (2200 University Club Drive, Austin, TX). The event, managed by Duchenne parents Tim and Laura Revell, is a Texas-style party big on food, fun and fundraising. Cost is \$150 per person and includes admission, food and beverages.

[Click here to register](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

**Research**

AVI BioPharma announces  
exon skipping trial results

Prosensa's Clinical  
Development Plan Update

ImagingDMD National  
Study Recruiting Patients

**News**

8-Year-Old to Climb Mt.  
Kilimanjaro to Cure  
Duchenne Muscular  
Dystrophy

Form a Climb to  
CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne  
Research

Sally and Mack Brown host  
3rd Annual Champions to  
CureDuchenne Fundraiser  
at The University of Texas  
Golf Club

Young Professionals Rally  
Around CureDuchenne

Shop to CureDuchenne

**Recent Successes**

AVI Announces Top Line  
Results for Exon Skipping  
Trial

**Family of the Month**

The Rothe Family

**Scientist of the Month**

Barry Byrne, M.D., Ph.D.

**Upcoming Events**

Champions to  
CureDuchenne Austin  
Gala, April 27, 2012,  
Austin, TX

Dealing for Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June 2,

## Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2, 2012, Los Angeles

The 5th annual Dealing for Duchenne event is June 2, 2012 at 6:00 p.m. at the legendary Sony Pictures Studios. The evening will sparkle with Hollywood magic and include a celebrity poker tournament and charity gambling, amazing auction, special live musical guest and dinner by Wolfgang Puck. The star-studded event committee includes Seal, Mandy Moore, Molly Ringwald and Anne Heche, to name a few. Proceeds will benefit the Center for Duchenne Muscular Dystrophy at UCLA.

[Click here to register](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.



### Research

AVI BioPharma announces exon skipping trial results

Prosenza's Clinical Development Plan Update

ImagingDMD National Study Recruiting Patients

### News

8-Year-Old to Climb Mt. Kilimanjaro to Cure Duchenne Muscular Dystrophy

Form a Climb to CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne Research

Sally and Mack Brown host 3rd Annual Champions to CureDuchenne Fundraiser at The University of Texas Golf Club

Young Professionals Rally Around CureDuchenne

Shop to CureDuchenne

### Recent Successes

AVI Announces Top Line Results for Exon Skipping Trial

### Family of the Month

The Rothe Family

### Scientist of the Month

Barry Byrne, M.D., Ph.D.

### Upcoming Events

Champions to CureDuchenne Austin Gala, April 27, 2012, Austin, TX

Dealing for Duchenne - Champions to CureDuchenne Los Angeles Gala, June 2,

## Climb to CureDuchenne, Pick Your Peak, June 23 and June 30, Nationwide

Teams of people from around the United States pick a mountain, hill or tall building to climb to raise funds and awareness for Duchenne. The fourth annual event features the Elite Team, led by 8-year-old Tyler Armstrong, of Yorba Linda, climbing 19,341 ft. to the summit of Mt. Kilimanjaro in Africa. Armstrong is one of the youngest to climb Mt. Kilimanjaro and is serving as the Honorary Spokesperson for the 2012 event.

- **What:** Teams of people across the country climb a mountain, hill or tall building to raise funds and awareness for CureDuchenne. This is the fourth annual event and hundreds of people will participate. All funds donated will be used for research and to raise awareness for Duchenne.
- **Where:** No geographic limitations. Anyone, regardless of athletic ability, is encouraged to participate individually or to form a team and secure personal sponsors/contributors for completing the climb.
- **When:** June 23, 2012 or June 30, 2012. If those dates do not work for you, please select another day that is more convenient. (Elite team to climb Mount Kilimanjaro June 25 - July 2, 2012)
- **Cost:** Registration fee is \$25, includes CureDuchenne t-shirts.

[Click here to register](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.

**Research**

AVI BioPharma announces  
exon skipping trial results

Prosenza's Clinical  
Development Plan Update

ImagingDMD National  
Study Recruiting Patients

**News**

8-Year-Old to Climb Mt.  
Kilimanjaro to Cure  
Duchenne Muscular  
Dystrophy

Form a Climb to  
CureDuchenne Team

I Am a Duchenne Dad

Fundraising for Duchenne  
Research

Sally and Mack Brown host  
3rd Annual Champions to  
CureDuchenne Fundraiser  
at The University of Texas  
Golf Club

Young Professionals Rally  
Around CureDuchenne

Shop to CureDuchenne

**Recent Successes**

AVI Announces Top Line  
Results for Exon Skipping  
Trial

**Family of the Month**

The Rothe Family

**Scientist of the Month**

Barry Byrne, M.D., Ph.D.

**Upcoming Events**

Champions to  
CureDuchenne Austin  
Gala, April 27, 2012,  
Austin, TX

Dealing for Duchenne -  
Champions to  
CureDuchenne Los  
Angeles Gala, June 2,

**Getzlaf Golf Shootout, September 8-9, 2012, Dana Point, Calif.**

The Getzlaf Golf Shootout is a spectacular, two-day charity celebration held at the beautiful Monarch Beach Golf Links in Dana Point and Sutra in Costa Mesa. Gold medalist and NHL All-Star Ryan Getzlaf, along with a host of other NHL stars, celebrities, and community leaders, will come together in support of CureDuchenne. Foursomes cost \$2,800 and include a celebrity or athlete as a fifth golfer plus eight tickets to the pre-golf dinner reception.

A pre-golf dinner and live auction will be held on Saturday, September 8 from 5:30 p.m. 9:30 p.m. at Sutra in Costa Mesa. The golf tournament is Sunday, September 9 at Monarch Beach Golf Links in Dana Point. Registration is at 9:00 a.m., shotgun at 10:30 a.m. and awards ceremony is at 4:00 p.m.

[Click here to register.](#)

2012, Los Angeles

Climb to CureDuchenne,  
Pick Your Peak, June 23  
and June 30, Nationwide

Getzlaf Golf Shootout,  
September 8-9, 2012, Dana  
Point, Calif.